96T

serum, plasma

Human

Enzyme immunoassay for the qualitative or quantitative determination of IgM antibodies against the viral capsid antigen (VCA) of Epstein-Barr virus (EBV) in human serum and plasma.

Microtiter plate: 1 x 12 x 8
Antigen Conjugate: 1 x 12 mL
Enzyme Tracer Concentrate (100x): 1 x 200 µL
Negative Control: 1 x 1.5 mL
Positive Control: 1 x 1.5 mL
Standard A-D: 1 x 4 x 1.5 mL
Diluent Buffer: 1 x 100 mL
Wash Buffer, Concentrate (10x): 1 x 100 mL
TMB Substrate Solution: 1 x 15 mL
TMB Stop Solution: 1 x 15mL

2-8°C

2 - 200 U/ml

Infectious mononucleosis is an acute lymphoproliferative disease that is common in children and young adults and is caused by the Epstein-Barr virus (EBV). The EBV is one of the herpes viruses 4 (gamma).
Characteristic clinical features include:

1. fever, sore throat, and lymhadenopathy
2. an associated absolute lymphocytosis greater than 50%, containing at least 10% of atypical lymphocytes in the peripheral blood
3. development of transient heterophil and persistent antibody responses against EBV
4. abnormal liver function tests

4% of infected young adults show an icteric manifestation and 50% have splenomegaly. In addition, EBV is implicated in nasopharyngeal carcinoma, Burkitt lymphoma and Hodgkin´s disease.
An infectious mononucleosis similar syndrome can be caused by cytomegalovirus, toxoplasmosis and other viral infection; differential diagnosis depends on laboratory results, with only EBV stimulating the production of heterophil antibodies.
EBV is present in saliva of patients with acute infectious mononucleosis, and excretion of the virus from the oropharynx, which persists for several months after the outbreak of the disease, is one of the major ways of virus transmission. Infected persons keep the Epstein-Barr virus for lifetime, but are mostly asymptomatic. In developing countries practically the whole population is infected; in western countries prevalence is about 80 – 90%. Transmission, possibly from the mother, already takes place at child's age and mainly via saliva.
Of great importance for diagnosis is the detection of an increase in relative and absolute number of lymphocytes and atypical lymphocytes. During the disease 50 – 60% of leukocytes in the peripheral blood can be lymphatic cells, of which normally 10% are atypical lymphocytes. In addition, abnormal liver function tests and high titers of heterophil antibodies are seen.
Serological tests like ELISA are very useful for the detection of anti-EBV antibodies, especially if heterophil antibodies are absent. The different stages of an EBV infection (acute, reactivated, past) are characterized by the appearance of different antibodies (IgA, IgG, IgM) against different viral antigens (virus capsid antigen = VCA, early antigen = EA and Epstein-Barr virus nuclear antigen = EBNA).
The six parameters produced by CD (VCA IgA / IgG / IgM, EA IgA / IgG und EBNA IgG) enable to detect and differentiate all stages of an EBV infection. A well directed selection of antigens for CD EBV ELISAs results in an extraordinary sensitivity and specificity for the diagnosis of acute diseases and for the detection of past infections.
The assays for the detections of antibodies against EA and EBNA use highly specific recombinant antigens – EA p54 antigen expressed in E. coli and EBNA-1 p72 antigen expressed in Sf9 cells; affinity purified VCA gp125 from P3HR1 cells is responsible for the high sensitivity of the VCA ELISAs.
This selection of antigens together with a purposeful regulation of assay characteristics results in a clear distinction between positive and negative samples, i.e. a small grey zone.
The very high sensitivity of the VCA IgA assay and the 100% specificity of the EA IgA ELISA are of particular importance; the combination of these two assays allows the correct detection of reactivated infections with extremely high reliability.
The ?-capture principle applied for the VCA IgM assay results in a higher specificity compared to IgM ELISAs following the sandwich principle, i.e. false positive results are minimized.
Information about antibody combinations that are typical for the different stages of an infection is given in chapter PERFORMANCE.